Search results
Results from the WOW.Com Content Network
Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [7] [8] It has been found to decrease the risk of fractures of the spine. [7] Common side effects include headache, joint pain, and injection site ...
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ...
To change this template's initial visibility, the |state= parameter may be used: {{Drugs for treatment of bone diseases | state = collapsed}} will show the template collapsed, i.e. hidden apart from its title bar. {{Drugs for treatment of bone diseases | state = expanded}} will show the template expanded, i.e. fully visible.
Bisphosphonates are used to treat osteoporosis, osteitis deformans (Paget's disease of the bone), bone metastasis (with or without hypercalcemia), multiple myeloma, and other conditions involving fragile, breakable bone. In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate.
The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.
The main groups of drugs involved are anti-resorptive drugs, and anti-angiogenic drugs. This condition was previously known as bisphosphonate-related osteonecrosis of the jaw ( BON or BRONJ ) because osteonecrosis of the jaw correlating with bisphosphonate treatment was frequently encountered, with its first incident occurring in 2003.
Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. [1] The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by ...
Additionally, greater BMD increase at 6, 12 and 18 months in spinal, hips and femoral bones was observed in abaloparatide compared to placebo and teriparatide-treated subjects. [ 21 ] Participants who completed 18 months of abaloparatide or placebo in the ACTIVE study were invited to participate in an extended open-labeled study - ACTIVExtend ...